Marta Krejčí

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 427 citations

Bone Disease, Hematological Malignancy, Bone Health +10

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

Luděk Pour, Henrieta Grešlíková, Renata Kupská et al. · Haematologica · 2013 · 179 citations · Full text

Melphalan 140 mg/m ² or 200 mg/m ² for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Holger W. Auner, Simona Iacobelli, Giulia Sbianchi et al. · Haematologica · 2017 · 84 citations · Full text

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

Marta Krejčí, Michael Doubek, Tomáš Büchler et al. · Annals of Hematology · 2005 · 83 citations

Mycophenolate Mofetil, Transplantation, Xenotransplantation +5

Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy

Pavel Němec, Zuzana Zemanová, Henrieta Grešlíková et al. · Biology of Blood and Marrow Transplantation · 2009 · 70 citations · Full text